LONDON (Reuters) - Results of a clinical study to be presented next month show the blockbuster inhaled lung drug Spiriva, marketed by Pfizer and Boehringer Ingelheim, actually cuts heart risk, ...

Spiriva (tiotropium bromide) is an anticholinergic medication that relaxes airway muscles to ease breathing in chronic obstructive pulmonary disease (COPD) and asthma. It’s meant for long-term daily ...

(Reuters) -Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German drugmaker said on ...

Lupin has received the Food and Drug Administration’s permission for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic of Boehringer Ingelheim’s Spiriva HandiHaler. The ...

Theravance has been heavily focused on completing the PIFR-2 head-to-head trial ever since it cut its inhaled Janus kinase (JAK) inhibitor program nezulcitinib back in February of 2023. (Stock ...

Boehringer Ingelheim today announced the launch of its new direct-to-consumer platform, "Boehringer Ingelheim Access." The platform will offer a convenient way for patients in the U.S. to order and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Lupin’s 18 µg capsules of tiotropium bromide inhalation powder, according to a manufacturer ...

Lupin has become the first company to score approval in the U.S. for its generic version of Boehringer Ingelheim’s COPD treatment Spiriva HandiHaler. (Lupin) Lupin of India has become the first ...